RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

NCT02065375 PHASE2 COMPLETED Results posted

This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.

Details

Lead sponsor	Biogen
Phase	PHASE2
Status	COMPLETED
Enrolment	109
Start date	Fri Feb 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Sep 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Inflammation and Pain Following Ocular Surgery

Interventions

• Omaveloxolone Ophthalmic Suspension 1.0%
• Omaveloxolone Opthalmic Suspension 0.5%
• Placebo

Countries

United States